

Navigating Medication Options:

Patient Centered Approaches to Opioid
Use Disorder during Pregnancy

Lauren K. Graber MD, MPH
Hennepin Healthcare
Family Medicine & Addiction Medicine
October 23, 2024

Disclosures

- None

Gratitudes

- Cresta Jones
- Brian Grahan
- Cindy Yang
- Makela Roberts-Virden & Project CHILD team
- Valerie Gustafson
- Gretchen Buchanan
- HCMC Labor & Delivery and Postpartum Teams

So many questions emerge when you are pregnant & using substances

Am I going to get in legal trouble?

Am I going to get sick?

Is she asking me this because of my race?

Are the drugs affecting my baby?

Are they going to make me go to treatment?

Will they believe me?

Are they going to take away my baby?

Will a medicine actually help me?

Are they going to commit me?

Is my baby going to go through withdrawal?

Can I trust them?

Do they think I'm drug seeking?

So many questions emerge when you are pregnant & using substances

Am I going to get in legal trouble?

Am I going to get sick?

Is she asking me this because of my race?

Are the drugs affecting my baby?

Are they going to make me go to treatment?

Will they believe me?

Are they going to take away my baby?

Will a medicine actually help me?

Are they going to commit me?

Is my baby going to go through withdrawal?

Can I trust them?

Do they think I'm drug seeking?

Objectives for today

1. Describe **different medications** for Opioid Use Disorder
2. Consider **risks & benefits** of these options for the pregnant person & the fetus
3. Discuss different ways to **initiate** buprenorphine & methadone
4. Navigate **intrapartum and postpartum pain** for patients on MOUD

Why is this important?

- National maternal drug overdose mortality rates have increased

Pregnant or postpartum

Reproductive age

Table. Drug Overdose Mortality Rates Among Pregnant or Postpartum Persons and Those of Reproductive Age From 2017 to 2020*


Year	Pregnant or postpartum			Reproductive age (aged 15-44 y) ^b		
	No. of persons	No. of live births ^c	Drug overdose mortality rate per 100 000 (95% CI) ^d	No. of persons	Population	Drug overdose mortality rate per 100 000 (95% CI) ^d
2017	252	3 844 260	6.56 (5.78-7.43)	9191	63 958 243	14.37 (14.08-14.67)
2018	266	3 780 401	7.04 (6.23-7.95)	9198	64 171 698	14.33 (14.04-14.63)
2019	304	3 736 144	8.14 (7.26-9.12)	9433	64 325 356	14.66 (14.37-14.96)
2020	427	3 602 653	11.85 (10.77-13.05)	12 756	64 543 832	19.76 (19.42-20.11)
Total	1249	14 963 458	8.35 (7.89-8.83)	40 578	256 999 129	15.79 (15.64-15.94)
Absolute change rate (95% CI) [relative change %]^e						
2017-2020			5.30 (3.90-6.71) [80.81]			5.39 (4.94-5.84) [37.53]
2019-2020			3.72 (2.25-5.20) [45.67]			5.10 (4.65-5.55) [34.77]

80.8% vs 37.5% increase

Bruzelius & Martins, 2022

Why is this important?

- National maternal drug overdose mortality rates have increased **particularly for pregnant & late postpartum patients**



Bruzelius & Martins, 2022

When starting these conversations

- Start with evidence based statements

Opioids & Fentanyl do NOT cause cognitive or developmental concerns for infants

Most substances impact a baby's growth & can make them come early


Alcohol, tobacco & cannabis have been associated with cognitive deficits in children

Children exposed to opioids in utero have the same developmental outcomes as children who were not

Babies cannot be born “addicted,” but their bodies will have been exposed to opioids, and they will need to transition

Medications for OUD save lives


So then why do we worry about opioid use in pregnancy?



Medications for OUD improve ALL of these


Without Medications for OUD

>85% of people return to illicit use



- Lower treatment retention
- Increased risk of overdose
 - Decreased tolerance
- Yet, this may be where your patient is ready to start
- **Prenatal care alone improves outcomes for those with OUD!**

Impact of Chronic Opioid Use & MOUD



Medications for Opioid Use Disorder (MOUD)

Methadone



Buprenorphine



Naltrexone



What is Methadone?



- **Full Opioid Agonist & Long Half Life**

- Onset within 30-60 min
- Half life 18-50 hours
- 30-60mg relieves acute withdrawal
- >80mg to extinguish craving and “blockade”
- Several medication interactions

- **Highly Regulated**

- Illegal to prescribe methadone for OUD in general practice
- Since March 2022 – for institutions that have applied to the DEA, there is a 3-day exception for inpatients as a bridge to an intake appointment at a methadone clinic (21 CFR 1306)

What is Methadone?



- **Opioid Treatment Programs (OTPs)**
 - “Methadone Clinic”
 - Supervised daily liquid administration
 - Opportunities for “take home” doses (but only after several months)
 - Counseling by Licensed Alcohol & Drug Counselor
 - Urine testing
 - BUT psychiatric, medical services often not provided
- **Relationships are important!**
 - Connecting patients to a program is critical

What is Buprenorphine?




- **Partial Opioid Agonist**


- Less respiratory depression
- Sublingual (poor bioavailability) 8-24 hours
- Long acting injectables 7- 28 days
- Goal dose usually 16-24mg/day

- **Accessible**

- No X waiver needed to prescribe
- Any provider with a DEA
- Allows for split dosing throughout the day



What is Buprenorphine?



- **Suboxone vs Subutex**

- Suboxone = buprenorphine + naloxone
- Subutex = buprenorphine only
- In pregnancy, both are very safe & effective

- **Precipitated withdrawal**

- It's not the naloxone that does this!
- Buprenorphine itself bumps off other full opioid agonists
- Timing of initiation is key
- Can be a deterrent for patients who have had a bad experience

What is Naltrexone?



- **Opioid Antagonist**

- Blocks any opioid with no physical dependence
- Option for unintentional exposures
- Pill or IM

- **Accessible**

- Available in most office settings
- Effective for alcohol use disorder & opioid use disorder


- **Withdrawal Potential**

- For those with opioid tolerance, can cause acute withdrawal
- Wait 7 days after last use

28% of participants drop out prior to getting naltrexone



Which medication is best for my patient?



Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support			
Access to treatment			
Avoids withdrawal for initiation			
Treatment automatically coordinated			
Maternal medical complications			
Long-term outcome			
Neonatal			
Birthweight			
Gestational age			
Breastfeeding			
% requiring NAS treatment			
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment			
Avoids withdrawal for initiation			
Treatment automatically coordinated			
Maternal medical complications			
Long-term outcome			
Neonatal			
Birthweight			
Gestational age			
Breastfeeding			
% requiring NAS treatment			
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation			
Treatment automatically coordinated			
Maternal medical complications			
Long-term outcome			
Neonatal			
Birthweight			
Gestational age			
Breastfeeding			
% requiring NAS treatment			
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation	✓		
Treatment automatically coordinated			
Maternal medical complications			
Long-term outcome			
Neonatal			
Birthweight			
Gestational age			
Breastfeeding			
% requiring NAS treatment			
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation	✓		
Treatment automatically coordinated	✓		
Maternal medical complications			
Long-term outcome			
Neonatal			
Birthweight			
Gestational age			
Breastfeeding			
% requiring NAS treatment			
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation	✓		
Treatment automatically coordinated	✓		
Maternal medical complications		✓	✓
Long-term outcome			
Neonatal			
Birthweight			
Gestational age			
Breastfeeding			
% requiring NAS treatment			
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation	✓		
Treatment automatically coordinated	✓		
Maternal medical complications		✓	✓
Long-term outcome	✓		
Neonatal			
Birthweight			
Gestational age			
Breastfeeding			
% requiring NAS treatment			
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation	✓		
Treatment automatically coordinated	✓		
Maternal medical complications		✓	✓
Long-term outcome	✓		
Neonatal			
Birthweight		✓	✓
Gestational age			
Breastfeeding			
% requiring NAS treatment			
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation	✓		
Treatment automatically coordinated	✓		
Maternal medical complications		✓	✓
Long-term outcome	✓		
Neonatal			
Birthweight		✓	✓
Gestational age		✓	✓
Breastfeeding			
% requiring NAS treatment			
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation	✓		
Treatment automatically coordinated	✓		
Maternal medical complications		✓	✓
Long-term outcome	✓		
Neonatal			
Birthweight		✓	✓
Gestational age		✓	✓
Breastfeeding	✓	✓	✓
% requiring NAS treatment			
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation	✓		
Treatment automatically coordinated	✓		
Maternal medical complications		✓	✓
Long-term outcome	✓		
Neonatal			
Birthweight		✓	✓
Gestational age		✓	✓
Breastfeeding	✓	✓	✓
% requiring NAS treatment			✓
Severity of NAS symptoms			
Duration of NAS treatment			

Which medication is best for my patient?

Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation	✓		
Treatment automatically coordinated	✓		
Maternal medical complications		✓	✓
Long-term outcome	✓		
Neonatal			
Birthweight		✓	✓
Gestational age		✓	✓
Breastfeeding	✓	✓	✓
% requiring NAS treatment			✓
Severity of NAS symptoms		✓	n/a
Duration of NAS treatment			

Which medication is best for my patient?


Key considerations:

- Patient preference
- Access to care

Summary of outcomes	FAVORS Methadone	FAVORS Buprenorphine	FAVORS Naltrexone
Maternal			
Treatment efficacy	✓	✓	✓
Craving support	✓	✓	
Access to treatment		✓	✓
Avoids withdrawal for initiation	✓		
Treatment automatically coordinated	✓		
Maternal medical complications		✓	✓
Long-term outcome	✓		
Neonatal			
Birthweight		✓	✓
Gestational age		✓	✓
Breastfeeding	✓	✓	✓
% requiring NAS treatment			✓
Severity of NAS symptoms		✓	n/a
Duration of NAS treatment		✓	n/a

Fetal Monitoring


- MOUD may affect NST results
- Interpret antenatal testing with caution within 2 hours of a dose



Salisbury 2012

Key Considerations in starting MOUD

- **YOU can do this!!**
- **Is the patient in withdrawal?**
 - Makes it hard to weigh medical decisions
 - Very okay to offer options and then decide in the future if patient would like to continue
 - Most important thing is to help them feel better
- **Methadone can be given any time, withdrawal or not**
 - Monitor 2 hours after dose for sedation
 - Be familiar with methadone clinics for referral
- **If COWS >8, give full dose buprenorphine!**
 - Low risk at this time for precipitated withdrawal




How to Start Buprenorphine

Assess withdrawal status

COWS >8

1. Give bup-nal 8-2mg right away

2. Can increase to 16-24*mg/day as needed



COWS <8

1. Start bup 0.5mg*** every 4-6 hours x 3 doses

2. Give bup-nal 1mg every 4-6 hours x 3 doses

3. Start bup-nal 8-2mg BID-TID

Offer supportive care immediately:

Clonidine
Hydroxyzine
Gabapentin
Loperamide
Ondansetron
Lorazepam
Olanzapine
Hydromorphone**
Methadone**

* At initiation and in 3rd trimester, may need up to 32mg daily to stabilize

**In the urgent treatment of withdrawal & patient centered care, can use full opioid agonists for withdrawal

*** Bup 0.5mg or equivalent! Bup-nal 2-0.5mg FILMs cut in 1/4 OR Belbuca 450mcg buccal

How to Start Methadone

Day 1

- Give methadone 30mg ASAP
- Monitor 2 hours after dose for sedation/withdrawal
- Give additional 10mg if withdrawal persists

Day 2

- Give total daily dose from Day 1 (40mg)
- Monitor 2 hours after dose for sedation/withdrawal
- Give additional 10mg if withdrawal persists

Day 3

- Give total daily dose from Day 2 (50mg)
- Monitor 2 hours after dose for sedation/withdrawal
- Give additional 10mg if withdrawal persists

Days 4 (+)


- Give total daily dose from Day 3 (60mg)
- Continue to increase by 5mg every other day
- Monitor 2 hours after any dose change

• Then what?

- Help connect with a Methadone Program (OTP)
- For participating hospital pharmacies, you can give up to 3 days of liquid methadone as a bridge to methadone clinic appointment
- Make sure your discharge paperwork clearly states what their last dose of methadone was!

FAQs

- **What if my patient is scared that they are going to have precipitated withdrawal?**
 - Go slow!
 - Offer lower dose initiation of buprenorphine
 - Connect with the care team for fast response to pt needs
- **What if they do have precipitated withdrawal?**
 - Give more buprenorphine!
 - 16-32mg more helps flood the opioid receptors
 - Treat their symptoms with other medications
 - Give full opioid agonists (methadone, hydromorphone)
- **Does MOUD need to be started in the hospital?**
 - After 28-32 weeks gestation for fetal monitoring
 - History of preterm labor or poor cardiovascular capacity



Addressing Intrapartum Pain



- **Continue MOUD**

- Continue buprenorphine, ideally 16mg or less
- Continue methadone at full dose




- **Increase Full Opioid Agonists**

- If full opioid agonists are indicated, patient may need **1.5-3x usual dosing**
- Adjuvant medications too:
 - Gabapentin
 - Acetaminophen



- **Anesthesia**

- Consider transverse abdominus plane anesthetic block



Addressing Postpartum Pain



- **Continue MOUD**

- Continue buprenorphine, **back to prior to admission dose**
- Continue methadone at full dose




- **Continue Full Opioid Agonists**

- May need more frequent & higher dosing
- Continue **scheduled dosing**
- Adjuvant medications too:
 - Gabapentin
 - Acetaminophen




- **Follow up**

- Ensure everyone is aware of follow up plans to get next dose of MOUD
- Follow up plan for who will manage post-op or post-procedural pain



In summary

1. Perinatal substance use is risky, but treatable
2. Methadone, buprenorphine and naltrexone are options for pregnant people
3. Buprenorphine can be initiated as low or high dose
4. Perinatal pain management includes continuing MOUD



“I believe
you are a
great
parent”

E-MODULES | Perinatal Substance Use Workforce Development Project



These are free to access, and between 5 – 10 minutes in length. To be viewed, please follow this QR code:

TOPIC	SPEAKER
Prenatal Alcohol Exposure and Fetal Alcohol Spectrum Disorders (FASD)	<i>Cresta W. Jones, MD, FASAM, FACOG</i>
Medications for Alcohol Use Disorder (AUD) in Pregnancy	<i>Kurt Devine, MD, FASAM</i>
Overview of Medications for Opioid Use Disorder (MOUD) in Pregnancy	<i>Lauren Graber, MD, MPH</i>
Perinatal Pain Management for Patients with Opioid Use	<i>Lauren Graber, MD, MPH</i>
Medications for Opioid Use Disorder (MOUD): Pharmacology Basics	<i>Marah Czaja, PA-C</i>
Prenatal Care for Pregnant People Using Methamphetamine in Pregnancy	<i>Charles Schaubberger, MD, FACOG, DFASAM</i>
Intrapartum and Postpartum Care for People Using Methamphetamine in Pregnancy	<i>Charles Schaubberger, MD, FACOG, DFASAM</i>
Breastfeeding and Neonatal and Infant Outcomes in Pregnancies Complicated by Methamphetamine Use	<i>Charles Schaubberger, MD, FACOG, DFASAM</i>
Marijuana in Pregnancy and Breastfeeding	<i>Adrienne Richardson, MD</i>
The 5 Ss: A Conceptual Framework of Perinatal Mental Health	<i>Katie Thorsness, MD</i>
Harm Reduction and Perinatal Care	<i>Kari Rabi, MD</i>
Lactation and Perinatal Substance Use Disorders	<i>Meagan Thompson, DNP, APRN, CNM, PMHNP-BC</i>
Opioid Use Disorder in Pregnancy	<i>Meagan Thompson, DNP, APRN, CNM, PMHNP-BC</i>



Perinatal Substance Use ECHO



Join the new series now!

WHEN

(most) 2nd and 4th Wednesdays | 12:15 - 1:15 PM
Next session: November 13th Panel Discussion on The Role of Peer Recovery Doulas

WHAT

Educational sessions, case reviews and discussions of best practices and protocols focused on inpatient perinatal substance use and SUD in the obstetric unit.

WHO SHOULD JOIN

Teams consisting of:

- Labor and delivery/antepartum nurses
- Obstetric care professionals
- Nursing leadership (e.g. charge nurses)
- Unit/Service line administration
- Inpatient social workers
- Doulas

[ECHO Minnesota – Perinatal Substance Use](#)

Co-directed by Drs. Cresta Jones & Lauren Graber

Contact:

Rachel Langer | ECHO Project Coordinator
rachel.langer@hcmcd.org

Scan QR Code to Register





Thank you!!

Lauren Graber MD, MPH
lauren.graber@hcmed.org

References

- Atluru, Sreevalli MD; Bruehlman, Alyssa K. MD; Vaughn, Porcia MSIS; Schauberger, Charles W. MD, MS; Smid, Marcela C. MD, MS. Naltrexone Compared With Buprenorphine or Methadone in Pregnancy: A Systematic Review. *Obstetrics & Gynecology* 143(3):p 403-410, March 2024
- Bruzelius E, Martins SS. US Trends in Drug Overdose Mortality Among Pregnant and Postpartum Persons, 2017-2020. *JAMA*. 2022 Dec 6;328(21):2159-2161. doi: 10.1001/jama.2022.17045. PMID: 36472602; PMCID: PMC9856503.
- D'Onofrio G, Hawk KF, Perrone J, et al. Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. *JAMA Netw Open*. 2023;6(3):e236108
- Forray A, Foster D. Substance Use in the Perinatal Period. *Curr Psychiatry Rep*. 2015 Nov;17(11):91.
- Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. *N Engl J Med*. 2010 Dec 9;363(24):2320-31.
- Kaltenbach K, O'Grady KE, Heil SH, Salisbury AL, Coyle MG, Fischer G, Martin PR, Stine S, Jones HE. Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes. *Drug Alcohol Depend*. 2018 Apr 1;185:40-49.
- Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. *Lancet*. 2018 Jan 27;391(10118):309-318.
- Salisbury AL, Coyle MG, O'Grady KE, Heil SH, Martin PR, Stine SM, Kaltenbach K, Weninger M, Jones HE. Fetal assessment before and after dosing with buprenorphine or methadone. *Addiction*. 2012 Nov;107 Suppl 1(0 1):36-44.
- Suarez EA, Huybrechts KF, Straub L, Hernández-Díaz S, Jones HE, Connery HS, Davis JM, Gray KJ, Lester B, Terplan M, Mogun H, Bateman BT. Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy. *N Engl J Med*. 2022 Dec 1;387(22):2033-2044.
- Towers CV, Katz E, Weitz B, Visconti K. Use of naltrexone in treating opioid use disorder in pregnancy. *Am J Obstet Gynecol*. 2020 Jan;222(1):83.e1-83.e8. doi: 10.1016/j.ajog.2019.07.037. Epub 2019 Jul 31. Erratum in: *Am J Obstet Gynecol*. 2023 Jun;228(6):770.
- Wachman, Elisha M. MD; Saia, Kelley MD; Bressler, Jonathan; Werler, Martha ScD; Carter, Ginny RN, PhD; Jones, Hendree E. PhD. Case Series of Individuals Treated With Naltrexone During Pregnancy for Opioid and/or Alcohol Use Disorder. *Journal of Addiction Medicine* 18(3):p 288-292, 5/6 2024